Investigating new treatment targets for diffuse large B cell lymphoma
From pathogenesis to new therapeutic targets in diffuse large B cell lymphoma
This study is looking at a tough type of cancer called diffuse large B cell lymphoma (DLBCL) to find new ways to treat it by exploring the genes that might be causing the cancer to behave differently, and it’s for patients who are facing challenges with their current treatments.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Columbia University Health Sciences NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-10928175 on NIH RePORTER |
What this research studies
This research focuses on diffuse large B cell lymphoma (DLBCL), a type of cancer that is difficult to treat and remains incurable for about 30% of patients. The study aims to uncover new therapeutic targets by exploring the genetic complexity of DLBCL, particularly in non-coding regions of the genome that may harbor mutations affecting tumor behavior. By utilizing advanced techniques like CRISPR, the researchers will analyze regulatory elements in the genome to identify potential new treatment strategies. This could lead to more effective therapies tailored to the unique genetic makeup of each patient's cancer.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with diffuse large B cell lymphoma, particularly those who have not responded to current therapies.
Not a fit: Patients with other types of lymphoma or those who are not diagnosed with diffuse large B cell lymphoma may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to the development of more effective and personalized treatments for patients with diffuse large B cell lymphoma.
How similar studies have performed: Other research has shown promise in targeting genetic mutations in cancers, suggesting that this approach could yield significant advancements in treatment.
Where this research is happening
New York, United States
- Columbia University Health Sciences — New York, United States (Active)
Researchers
- Principal investigator: Dalla-Favera, Riccardo — Columbia University Health Sciences
- Study coordinator: Dalla-Favera, Riccardo
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.